Hypertrophic Cardiomyopathy: The Hidden Cause of Sudden Death in Young Athletes
Hypertrophic Cardiomyopathy is the most common inherited heart muscle disease and the leading identifiable cause of sudden cardiac death in young athletes worldwide. A seemingly fit, healthy young person collapses without warning during sport or exercise, and the devastating post-mortem finding reveals a thickened, structurally abnormal heart that had been silently dangerous for years. These tragedies are preventable, but only when the condition is identified before a catastrophic cardiac event occurs.
What makes Hypertrophic Cardiomyopathy particularly challenging is its deceptive nature. Most people who carry this genetic condition live entirely normal lives with no limiting symptoms, completely unaware that their heart harbours a potentially lethal abnormality. Others experience debilitating breathlessness, chest pain, and syncope that profoundly impair daily living. Understanding this condition in its full biological, clinical, and human complexity is essential for clinicians, athletes, families, and anyone invested in cardiac safety.
What Is Hypertrophic Cardiomyopathy?
Hypertrophic Cardiomyopathy, universally abbreviated as HCM, is a genetic heart muscle disease characterised by abnormal thickening of the left ventricular wall in the absence of any external cause such as hypertension or valve disease. The word hypertrophic means excessive growth, and cardiomyopathy means disease of the heart muscle.
In HCM, heart muscle cells called cardiomyocytes are arranged in a chaotic, disorganised pattern rather than the orderly alignment of normal myocardium. This cellular disarray, called myocyte disarray or myofibre disarray, creates an electrically unstable substrate predisposing the heart to dangerous arrhythmias.
The Structural Abnormalities of HCM
The left ventricular wall thickening in HCM can affect any region but most commonly involves the interventricular septum, the muscular wall separating the left and right ventricles. Asymmetric septal hypertrophy is the most characteristic pattern, though apical, concentric, and other distributions also occur.
Thickening impairs the ventricular cavity’s ability to fill normally during diastole, meaning the relaxation phase between heartbeats. The resulting diastolic dysfunction reduces cardiac output, particularly during exertion, explaining many of the symptoms people with HCM experience during physical activity.
Obstruction Versus Non-Obstruction
Approximately 70 percent of people with HCM develop some degree of left ventricular outflow tract obstruction, meaning the thickened septum physically narrows the passage through which blood exits the left ventricle into the aorta. This obstruction worsens during exertion when heart rate rises and ventricular volume decreases, creating the dynamic obstruction that characterises obstructive HCM.
The remaining 30 percent have non-obstructive HCM, where significant thickening and diastolic dysfunction cause symptoms without physical outflow obstruction. Both forms carry risk, though obstructive HCM produces more prominent symptoms and specific treatment targets.
Genetics and Inheritance of HCM
HCM is fundamentally a genetic disease, arising from mutations in genes encoding proteins that form the cardiac sarcomere, the basic contractile unit of heart muscle.
Sarcomere Gene Mutations
More than 1,500 distinct mutations across at least eight sarcomere genes cause HCM. The most commonly implicated genes encode beta-myosin heavy chain (MYH7) and myosin-binding protein C (MYBPC3), together accounting for approximately 70 to 80 percent of genetically identified HCM cases.
These mutations alter the structure and function of sarcomere proteins, disrupting the precise mechanical interactions that enable normal heart muscle contraction. The result is hypercontractility, meaning excessively forceful contraction, alongside impaired relaxation and the characteristic myocyte disarray.
Autosomal Dominant Inheritance
HCM follows an autosomal dominant inheritance pattern, meaning a person needs only one faulty gene copy, inherited from either parent, to develop the condition. Each child of an affected parent carries a 50 percent chance of inheriting the causative mutation.
Importantly, expression is highly variable. Family members carrying the identical mutation can show dramatically different degrees of hypertrophy and clinical severity. Some carry the mutation without developing any detectable thickening, a phenomenon called incomplete penetrance, making genetic cascade screening for family members complex but critically important.
Genetic Testing in Clinical Practice
Genetic testing for HCM identifies the causative mutation in approximately 40 to 60 percent of clinically diagnosed cases. A positive genetic result enables cascade screening of first-degree relatives, identifying mutation carriers who may not yet show echocardiographic changes.
Identifying mutation-positive, phenotype-negative relatives, meaning those with the gene but no current thickening, enables proactive surveillance that catches developing disease early and allows lifestyle and competitive sport decisions to be made on more informed grounds.
How Common Is Hypertrophic Cardiomyopathy?
HCM is the most common inherited cardiac condition, with an estimated prevalence of approximately one in 500 in the general population based on echocardiographic population studies. This translates to roughly 700,000 people in the United States and millions worldwide carrying the condition.
Despite this prevalence, HCM remains substantially underdiagnosed. Many people with HCM have minimal or no symptoms and never come to medical attention. Others receive incorrect diagnoses including hypertensive heart disease or athlete’s heart before HCM is correctly identified.
HCM Across Different Populations
HCM occurs across all racial and ethnic groups worldwide. Studies suggest similar genetic prevalence across diverse populations, though some variation in specific causative mutations exists between different ethnic groups. Access to echocardiographic diagnosis remains significantly less available in lower-income settings, contributing to underdiagnosis in many parts of the world.
Men receive HCM diagnoses more frequently than women in most clinical series, though this likely reflects referral bias and diagnostic patterns rather than true prevalence differences.
Why HCM Causes Sudden Cardiac Death in Athletes
The link between HCM and sudden cardiac death in young athletes involves multiple interacting mechanisms that converge lethally during intense physical exertion.
The Arrhythmia Mechanism
The chaotic myocyte disarray and patchy myocardial fibrosis, meaning scar tissue replacing normal muscle, in HCM create multiple abnormal electrical pathways within the ventricular wall. During exercise, accelerated heart rate, increased sympathetic nervous system activation, and heightened myocardial oxygen demand all interact with this unstable electrical substrate.
This combination can trigger ventricular fibrillation, a chaotic, disorganised electrical storm in the ventricles that immediately stops effective cardiac pumping and causes cardiac arrest within seconds if not treated with defibrillation.
Why Exercise Is the Trigger
Exercise dramatically increases cardiac demands and creates the precise haemodynamic and neurochemical conditions that unmask the dangerous electrical instability in HCM hearts. Dynamic outflow obstruction worsens during intense exercise, reducing cardiac output further. Ischaemia, meaning inadequate blood supply to the thickened muscle mass, contributes additional electrical instability.
The combination of outflow obstruction, diastolic dysfunction, myocardial ischaemia, and structural arrhythmia substrate converges most dangerously at peak exercise intensity, explaining why collapse typically occurs during or immediately after maximal athletic effort.
The Athlete’s Heart Diagnostic Challenge
An important diagnostic challenge is distinguishing HCM from physiological athlete’s heart, the normal cardiac adaptation to intensive training that also produces left ventricular wall thickening. Athlete’s heart typically shows symmetric, modest thickening below 13 millimetres, normal or enlarged cavity size, normal diastolic function, and complete regression with detraining.
HCM typically shows asymmetric thickening often exceeding 15 millimetres, reduced or normal cavity size, impaired diastolic function, and persistence or progression with detraining. A so-called grey zone exists between 13 and 15 millimetres where the distinction requires additional clinical, imaging, and sometimes genetic investigation.
Symptoms of Hypertrophic Cardiomyopathy
HCM produces a wide spectrum of symptoms ranging from complete clinical silence to severe functional limitation. Symptom severity correlates imperfectly with anatomical severity.
Exertional Breathlessness
Progressive exertional breathlessness is the most common symptom of HCM. It occurs because diastolic dysfunction impairs ventricular filling, reducing the cardiac output available during exercise. Additionally, outflow obstruction worsens during exertion in obstructive HCM, further limiting forward blood flow.
Many people unconsciously limit their activity over time to avoid breathlessness, adapting to reduced exercise capacity without recognising the deterioration occurring in their cardiac function.
Chest Pain
Chest pain in HCM typically occurs during exertion and reflects myocardial ischaemia, inadequate blood supply to the abnormally thickened, high-demand ventricular wall. The thickened muscle mass requires more oxygen than the coronary circulation can deliver, particularly during peak exercise when demands are greatest.
This angina-like pain differs from coronary artery disease chest pain in that the coronary arteries themselves are usually structurally normal in HCM. The imbalance between supply and demand rather than arterial blockage drives the ischaemia.
Syncope and Pre-Syncope
Syncope, meaning fainting, and pre-syncope, meaning near-fainting or dizziness, occur in HCM through several mechanisms. Exertional outflow obstruction can abruptly reduce cerebral perfusion during vigorous activity. Dangerous ventricular arrhythmias cause sudden cardiac arrest with loss of consciousness. Inappropriate vasodilation during exercise also contributes to blood pressure drops in some patients.
Exertional syncope in any young person demands immediate cardiological evaluation and should never be dismissed as benign without comprehensive investigation.
Palpitations
Palpitations reflect the variety of arrhythmias that HCM generates. Atrial fibrillation occurs in 20 to 25 percent of HCM patients over their lifetime, causing palpitations, breathlessness, and importantly, stroke risk from atrial thrombus formation. Ventricular premature beats and non-sustained ventricular tachycardia also produce palpitation symptoms.
Each arrhythmia in HCM requires specific risk assessment and management rather than generic reassurance.
Asymptomatic Disease
A significant proportion of people with HCM, particularly younger individuals, remain completely asymptomatic. Their condition surfaces only through family screening, incidental cardiac murmur detection, or tragically, sudden cardiac death. This silent majority underscores the vital importance of proactive HCM screening strategies, particularly in athletic populations and families of affected individuals.
Diagnosing Hypertrophic Cardiomyopathy
Accurate HCM diagnosis combines clinical assessment, imaging, electrocardiography, and genetic testing into a comprehensive evaluation.
The Role of Electrocardiography
Electrocardiography (ECG) is abnormal in approximately 75 to 95 percent of HCM cases, making it a valuable screening tool despite its non-specificity. Common ECG changes include left ventricular hypertrophy voltage criteria, repolarisation abnormalities, deep T-wave inversions particularly in lateral leads, and pathological Q waves in inferior and lateral leads.
An abnormal ECG in a young athlete without identified explanation warrants echocardiography and specialist cardiological evaluation. ECG-based pre-participation screening programmes specifically aim to identify these abnormalities before catastrophic events occur.
Echocardiography
Transthoracic echocardiography is the cornerstone of HCM diagnosis. It measures left ventricular wall thickness throughout the chamber, assesses cavity size, evaluates systolic and diastolic function, quantifies outflow obstruction gradients, and detects associated mitral valve abnormalities including systolic anterior motion of the anterior mitral leaflet into the outflow tract.
A maximum wall thickness of 15 millimetres or more in the absence of another cause confirms HCM diagnosis in adults. Thickness between 13 and 15 millimetres requires additional investigation to resolve the diagnostic uncertainty.
Cardiac MRI
Cardiac magnetic resonance imaging has become an indispensable tool in HCM assessment. MRI provides superior myocardial tissue characterisation compared to echocardiography, precisely measuring wall thickness in all ventricular segments and detecting late gadolinium enhancement, the MRI signature of myocardial fibrosis.
Fibrosis extent on cardiac MRI correlates strongly with sudden death risk, ventricular arrhythmia burden, and adverse clinical outcomes. Late gadolinium enhancement covering more than 15 percent of left ventricular mass identifies a particularly high-risk group warranting aggressive risk stratification and potentially ICD implantation.
Stress Testing
Exercise stress testing in HCM serves multiple purposes. It objectively assesses functional capacity, unmasks provocable outflow obstruction that may not be present at rest, evaluates blood pressure response during exercise, and detects exercise-induced arrhythmias. An abnormal blood pressure response, specifically failure to rise or a fall during exercise, independently predicts worse outcomes.
Stress testing in HCM should always occur in clinical settings with full resuscitation capabilities given the small but real risk of exercise-induced arrhythmia during the procedure.
Sudden Death Risk Stratification in HCM
Identifying which HCM patients face the highest sudden death risk and directing ICD therapy accordingly is the most consequential clinical decision in HCM management.
Established Risk Markers
Several established risk markers guide sudden death risk assessment in HCM. Prior cardiac arrest or sustained ventricular tachycardia represents the highest-risk category, marking secondary prevention ICD indications. Family history of HCM-related sudden cardiac death in one or more first-degree relatives, massive hypertrophy with wall thickness exceeding 30 millimetres, unexplained syncope especially in young patients, non-sustained ventricular tachycardia on ambulatory monitoring, and abnormal blood pressure response during exercise all independently contribute to risk.
Risk assessment tools including the HCM Risk-SCD calculator integrate multiple factors to estimate five-year sudden death probability, guiding ICD implantation decisions.
The Role of Cardiac MRI in Risk Stratification
Extensive late gadolinium enhancement on cardiac MRI has emerged as an important independent risk predictor. Several studies demonstrate that fibrosis burden predicts ventricular arrhythmia risk and sudden death probability beyond traditional clinical markers.
Contemporary risk stratification increasingly incorporates cardiac MRI findings alongside clinical risk factors, moving toward more individualised and biologically informed sudden death risk assessment.
Implantable Cardioverter-Defibrillator Therapy
ICDs are the only proven intervention for preventing sudden cardiac death in high-risk HCM patients. These implanted devices continuously monitor cardiac rhythm and deliver a lifesaving shock when they detect ventricular fibrillation or sustained ventricular tachycardia.
ICD implantation is appropriate in all HCM patients with prior cardiac arrest, sustained ventricular arrhythmia, or estimated five-year sudden death risk exceeding five to six percent based on validated risk calculators. Shared decision-making between clinicians and patients, incorporating individual risk estimates, lifestyle implications, and patient values, guides these consequential decisions.
Treatment of Hypertrophic Cardiomyopathy
HCM treatment addresses symptoms, prevents complications, and reduces sudden death risk through pharmacological, procedural, and surgical strategies.
Beta-Blockers and Calcium Channel Blockers
Beta-blockers remain the foundational pharmacological treatment for symptomatic obstructive HCM. By reducing heart rate and limiting the dynamic worsening of outflow obstruction during exertion, beta-blockers improve breathlessness and exercise tolerance. They also reduce myocardial oxygen demand, alleviating exertional chest pain.
Non-dihydropyridine calcium channel blockers, specifically verapamil, provide an alternative for those intolerant of beta-blockers, improving diastolic filling and reducing obstruction in many patients.
Mavacamten: A Disease-Specific Breakthrough
Mavacamten represents a landmark therapeutic advance, being the first cardiac myosin inhibitor specifically designed to treat the underlying sarcomere hypercontractility driving obstructive HCM. By directly reducing excessive myosin-actin cross-bridge formation, mavacamten decreases outflow obstruction, improves diastolic function, and reduces symptoms without the heart rate dependency of beta-blockers.
The EXPLORER-HCM trial demonstrated significant improvements in exercise capacity, outflow tract gradients, symptoms, and quality of life with mavacamten compared to placebo. This disease-specific mechanism-based therapy marks a paradigm shift in HCM pharmacology.
Septal Reduction Therapy
For patients with severe obstructive HCM refractory to maximal medical therapy, septal reduction procedures physically reduce septal thickness and relieve outflow obstruction. Two main approaches exist.
Surgical septal myectomy involves removing a portion of the hypertrophied septum through open-heart surgery. Performed at experienced centres, myectomy achieves excellent long-term symptom relief with low procedural mortality and remains the gold standard intervention for eligible patients.
Alcohol septal ablation delivers a small amount of alcohol through a coronary artery catheter to deliberately infarct a targeted septal region, reducing its thickness without surgery. This catheter-based approach suits patients who are poor surgical candidates due to age or comorbidity.
Managing Atrial Fibrillation in HCM
Atrial fibrillation in HCM requires aggressive management given its significant impact on symptoms and stroke risk. Rate control or rhythm control strategies address haemodynamic consequences. Anticoagulation with direct oral anticoagulants or warfarin reduces stroke risk, which is substantially elevated in HCM patients with atrial fibrillation regardless of other stroke risk factors.
Catheter ablation for atrial fibrillation offers rhythm restoration in selected patients, though recurrence rates are higher in HCM than in structurally normal hearts due to the underlying atrial remodelling.
Pre-Participation Screening for HCM in Athletes
The tragedy of HCM-related sudden death in athletes has driven sustained debate about how best to screen competitive athletes before allowing them to compete.
The European Versus American Screening Debate
European sports medicine organisations, led by Italian models pioneered in the Veneto region, historically advocated mandatory ECG-based pre-participation screening for competitive athletes. This approach, combining history, physical examination, and 12-lead ECG, demonstrated a significant reduction in HCM-related sudden death in screened Italian athletes over decades.
American guidelines historically relied on history and physical examination alone without routine ECG, citing concerns about false positive rates, costs, and practical implementation challenges in large athletic programmes.
Current Consensus and Best Practices
Contemporary evidence increasingly supports ECG inclusion in structured pre-participation screening, particularly for competitive athletes. Several sports medicine and cardiology societies have moved toward consensus recommending ECG as part of comprehensive athletic screening, though implementation varies considerably between countries, sporting levels, and healthcare systems.
Regardless of formal screening programme structure, any athlete with a family history of HCM or sudden cardiac death, exertional symptoms, or an audible cardiac murmur warrants comprehensive cardiological evaluation including echocardiography before athletic clearance.
Competitive Sport Participation After HCM Diagnosis
HCM diagnosis historically triggered blanket disqualification from most competitive sports based on perceived sudden death risk. Contemporary guidelines have evolved toward more individualised shared decision-making. Low-risk HCM patients with no high-risk features, ICD protection, and full understanding of residual risks may reasonably participate in certain competitive sports after thorough specialist evaluation.
This shift from paternalistic disqualification to informed shared decision-making better respects patient autonomy while maintaining appropriate clinical diligence.
Frequently Asked Questions
What is Hypertrophic Cardiomyopathy?
Hypertrophic Cardiomyopathy is a genetic heart muscle disease causing abnormal thickening of the left ventricular wall due to mutations in sarcomere proteins. The thickened, structurally disorganised muscle impairs cardiac filling, may obstruct blood outflow, and creates an electrically unstable substrate predisposing to dangerous arrhythmias. HCM is the most common inherited cardiac condition and the leading identifiable cause of sudden cardiac death in young athletes.
How is HCM inherited?
HCM follows an autosomal dominant inheritance pattern, meaning one faulty gene copy from either parent is sufficient to cause the condition. Each child of an affected parent has a 50 percent chance of inheriting the causative mutation. Expression varies widely between family members carrying identical mutations. Genetic cascade screening of first-degree relatives after a proband diagnosis enables early identification of at-risk family members.
Can people with HCM live normal lives?
Many people with HCM live long, relatively normal lives, particularly those with no significant symptoms or high-risk features. Appropriate specialist monitoring, guideline-directed therapy, and ICD implantation when indicated have transformed the natural history of HCM. Sudden death risk in unselected HCM populations is approximately one percent per year, substantially lower than earlier estimates from highly selected referral populations.
What is mavacamten and how does it help?
Mavacamten is a first-in-class cardiac myosin inhibitor that directly targets the excessive sarcomere contractility driving obstructive HCM. By reducing outflow obstruction and improving diastolic filling, mavacamten significantly improves breathlessness, exercise capacity, and quality of life in symptomatic obstructive HCM patients. It represents the first disease-specific pharmacological therapy addressing HCM’s underlying sarcomere hyperactivity rather than merely managing downstream consequences.
Should all young athletes be screened for HCM?
Pre-participation cardiovascular screening of competitive athletes, incorporating medical history, physical examination, and ideally a 12-lead ECG, offers the best currently available strategy for detecting HCM before catastrophic events occur. Any athlete with a family history of sudden cardiac death, exertional symptoms, or a cardiac murmur requires echocardiography and specialist evaluation regardless of formal screening programme structure.
Does HCM always cause sudden death?
No. Most people with HCM never experience sudden cardiac death, and many live entirely normal lifespans. Sudden death risk concentrates in identifiable high-risk subgroups characterised by prior cardiac arrest, family history of HCM sudden death, massive hypertrophy, unexplained syncope, extensive myocardial fibrosis, or dangerous arrhythmias on monitoring. ICD implantation provides effective protection in these high-risk individuals, converting a potential fatality into a treatable arrhythmia event.
Disclaimer:
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis, treatment, or medical guidance related to any health condition.
References:
- Hemochromatosis has variable presentations recognizable by iron-related organ damage (cirrhosis, cardiomyopathy,
- Normal pressure hydrocephalus is a neurological disorder where impaired CSF absorption leads to ventricular enlargement and progressive neurological dysfunction despite normal intracranial pressure.Â
- Systemic sclerosis is a chronic autoimmune connective tissue disease characterized by skin fibrosis and often involving internal organs.Â
- Brugada Syndrome is a rare genetic heart condition that affects how electrical signals move through the heart.Â
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
